Biotest Aktiengesellschaft (BIO) - Net Assets
Based on the latest financial reports, Biotest Aktiengesellschaft (BIO) has net assets worth €509.60 Million EUR (≈ $595.78 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.42 Billion ≈ $1.66 Billion USD) and total liabilities (€906.90 Million ≈ $1.06 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biotest Aktiengesellschaft (BIO) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €509.60 Million |
| % of Total Assets | 35.98% |
| Annual Growth Rate | 7.38% |
| 5-Year Change | 20.18% |
| 10-Year Change | 28.72% |
| Growth Volatility | 18.04 |
Biotest Aktiengesellschaft - Net Assets Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. See Biotest Aktiengesellschaft defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual net assets of Biotest Aktiengesellschaft from 2002 to 2024. For live valuation and market cap data, see BIO market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €530.70 Million ≈ $620.44 Million |
+6.37% |
| 2023-12-31 | €498.90 Million ≈ $583.27 Million |
+34.44% |
| 2022-12-31 | €371.10 Million ≈ $433.85 Million |
-2.44% |
| 2021-12-31 | €380.40 Million ≈ $444.73 Million |
-13.86% |
| 2020-12-31 | €441.60 Million ≈ $516.28 Million |
-7.40% |
| 2019-12-31 | €476.90 Million ≈ $557.55 Million |
-3.70% |
| 2018-12-31 | €495.20 Million ≈ $578.94 Million |
+42.38% |
| 2017-12-31 | €347.80 Million ≈ $406.61 Million |
-3.58% |
| 2016-12-31 | €360.70 Million ≈ $421.70 Million |
-12.52% |
| 2015-12-31 | €412.30 Million ≈ $482.02 Million |
-14.14% |
| 2014-12-31 | €480.20 Million ≈ $561.40 Million |
+4.23% |
| 2013-12-31 | €460.70 Million ≈ $538.61 Million |
+24.70% |
| 2012-12-31 | €369.43 Million ≈ $431.91 Million |
+6.57% |
| 2011-12-31 | €346.67 Million ≈ $405.29 Million |
+12.70% |
| 2010-12-31 | €307.61 Million ≈ $359.63 Million |
+13.99% |
| 2009-12-31 | €269.86 Million ≈ $315.50 Million |
+6.51% |
| 2008-12-31 | €253.37 Million ≈ $296.22 Million |
+12.23% |
| 2007-12-31 | €225.76 Million ≈ $263.94 Million |
+25.90% |
| 2006-12-31 | €179.31 Million ≈ $209.64 Million |
+6.12% |
| 2005-12-31 | €168.97 Million ≈ $197.55 Million |
+56.51% |
| 2004-12-31 | €107.97 Million ≈ $126.22 Million |
+4.53% |
| 2003-12-31 | €103.29 Million ≈ $120.75 Million |
-6.78% |
| 2002-12-31 | €110.79 Million ≈ $129.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biotest Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 27450000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €274.50 Million | 51.72% |
| Common Stock | €39.60 Million | 7.46% |
| Other Components | €216.60 Million | 40.81% |
| Total Equity | €530.70 Million | 100.00% |
Biotest Aktiengesellschaft Competitors by Market Cap
The table below lists competitors of Biotest Aktiengesellschaft ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
$976.41 Million |
|
Chengdu Zhimingda Electronics Co. Ltd. A
SHG:688636
|
$976.44 Million |
|
Haima Automobile Group Co Ltd
SHE:000572
|
$977.09 Million |
|
Suzhou Medsys Tech Co Ltd
SHG:603990
|
$977.50 Million |
|
Shanghai Urban Architecture Design Co. Ltd.
SHE:300983
|
$976.04 Million |
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
$975.70 Million |
|
DBV Technologies S.A.
PA:DBV
|
$975.59 Million |
|
Allianz Malaysia Bhd
KLSE:1163
|
$975.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotest Aktiengesellschaft's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 498,900,000 to 530,700,000, a change of 31,800,000 (6.4%).
- Net income of 26,400,000 contributed positively to equity growth.
- Dividend payments of 1,600,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,100,000.
- Other factors increased equity by 8,100,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €26.40 Million | +4.97% |
| Dividends Paid | €1.60 Million | -0.3% |
| Other Comprehensive Income | €-1.10 Million | -0.21% |
| Other Changes | €8.10 Million | +1.53% |
| Total Change | €- | 6.37% |
Book Value vs Market Value Analysis
This analysis compares Biotest Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.15x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.54x to 3.15x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | €4.43 | €42.20 | x |
| 2003-12-31 | €4.18 | €42.20 | x |
| 2004-12-31 | €4.34 | €42.20 | x |
| 2005-12-31 | €6.33 | €42.20 | x |
| 2006-12-31 | €5.52 | €42.20 | x |
| 2007-12-31 | €6.78 | €42.20 | x |
| 2008-12-31 | €7.07 | €42.20 | x |
| 2009-12-31 | €7.52 | €42.20 | x |
| 2010-12-31 | €8.57 | €42.20 | x |
| 2011-12-31 | €9.85 | €42.20 | x |
| 2012-12-31 | €10.50 | €42.20 | x |
| 2013-12-31 | €12.32 | €42.20 | x |
| 2014-12-31 | €12.13 | €42.20 | x |
| 2015-12-31 | €10.42 | €42.20 | x |
| 2016-12-31 | €9.11 | €42.20 | x |
| 2017-12-31 | €8.78 | €42.20 | x |
| 2018-12-31 | €12.51 | €42.20 | x |
| 2019-12-31 | €12.05 | €42.20 | x |
| 2020-12-31 | €11.16 | €42.20 | x |
| 2021-12-31 | €9.61 | €42.20 | x |
| 2022-12-31 | €9.38 | €42.20 | x |
| 2023-12-31 | €12.61 | €42.20 | x |
| 2024-12-31 | €13.41 | €42.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotest Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.64%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.70x
- Recent ROE (4.97%) is above the historical average (4.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 18.64% | 7.68% | 0.69x | 3.50x | €9.18 Million |
| 2003 | -5.22% | -2.36% | 0.63x | 3.49x | €-15.29 Million |
| 2004 | 5.62% | 2.69% | 0.61x | 3.44x | €-4.55 Million |
| 2007 | 7.77% | 5.29% | 0.61x | 2.41x | €-4.97 Million |
| 2008 | 11.30% | 7.29% | 0.65x | 2.38x | €3.23 Million |
| 2009 | 10.58% | 7.18% | 0.62x | 2.39x | €1.54 Million |
| 2010 | 13.09% | 9.57% | 0.65x | 2.10x | €9.33 Million |
| 2011 | 13.89% | 11.41% | 0.62x | 1.97x | €13.49 Million |
| 2012 | 9.05% | 7.59% | 0.64x | 1.85x | €-3.52 Million |
| 2013 | 6.95% | 6.39% | 0.56x | 1.92x | €-14.06 Million |
| 2014 | 4.00% | 3.30% | 0.56x | 2.15x | €-28.81 Million |
| 2015 | -20.01% | -13.99% | 0.61x | 2.34x | €-123.72 Million |
| 2016 | -12.70% | -8.28% | 0.59x | 2.59x | €-81.85 Million |
| 2017 | -1.01% | -0.93% | 0.39x | 2.82x | €-38.26 Million |
| 2018 | 36.71% | 45.39% | 0.38x | 2.11x | €132.20 Million |
| 2019 | -0.99% | -1.12% | 0.38x | 2.32x | €-52.39 Million |
| 2020 | -7.11% | -6.48% | 0.43x | 2.56x | €-75.56 Million |
| 2021 | -16.67% | -12.30% | 0.47x | 2.90x | €-101.44 Million |
| 2022 | -8.54% | -6.14% | 0.43x | 3.24x | €-68.81 Million |
| 2023 | 25.46% | 18.55% | 0.49x | 2.83x | €77.11 Million |
| 2024 | 4.97% | 3.64% | 0.51x | 2.70x | €-26.67 Million |
Industry Comparison
This section compares Biotest Aktiengesellschaft's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotest Aktiengesellschaft (BIO) | €509.60 Million | 18.64% | 1.78x | $976.15 Million |
| Covestro AG (1COV) | $5.25 Billion | 10.51% | 1.19x | $11.10 Billion |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $70.69 Million |
| COINSHARES I. LS-000247 (3TW) | $304.77 Million | 19.41% | 10.42x | $472.53 Million |
| Adaptimmune Therapeutics plc (473A) | $202.98 Million | -34.55% | 0.39x | $42.94 Million |
| KINGMAN MINERALS LTD. (47A) | $1.17 Million | -63.86% | 0.49x | $267.57K |
| GENOR BIOPHARMA DL-00002 (67N0) | $1.81 Billion | -40.45% | 0.17x | $120.83 Million |
| Biotest Aktiengesellschaft (BIO3) | $253.37 Million | 11.10% | 1.34x | $656.94 Million |
| Bancolombia S.A (BXK) | $33.93 Trillion | 12.05% | 7.54x | $4.84 Billion |
| mVISE AG (C1V) | $3.44 Million | -64.81% | 3.31x | $10.43 Million |
About Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more